At Amylyx our moments are spent in the pursuit of furthering treatment for those living with neurodegenerative diseases. Every day presents an opportunity to turn these rapidly progressing diseases into conditions that can be managed medically, and effectively. With the end goal of giving people more quality time with the ones they love.
I feel like Amylyx is a very different company than most that I work with and truly seems like a company that cares, with a big heart, but further than that is you have a fierceness in you and you're not going to back down from so many of the obstacles that ALS patients have been facing. What started as a question into how neurons die, became a promising step forward in neurodegenerative disease treatment.
I feel like Amylyx is a very different company than most that I work with and truly seems like a company that cares, with a big heart, but further than that is you have a fierceness in you and you're not going to back down from so many of the obstacles that ALS patients have been facing. What started as a question into how neurons die, became a promising step forward in neurodegenerative disease treatment.
Services
Amylyx is a Cambridge-based pharmaceutical company dedicated to the development of therapeutics for the treatment of neurodegenerative disorders. Guided by our core values, we incorporate unconventional approaches through strong partnerships with industry leaders, scientists, doctors and organizations.
When it comes to finding a cure for neurodegenerative diseases, our team won't take no for an answer. Progress is made possible thanks to the passion and drive of every Amylyx team member. Debra Canner joined Amylyx in 2019 as Global Head of Human Resources, and she currently oversees all human resources efforts.
Dr. Cheng joined Morningside in 2006 and focuses on biopharmaceutical and healthcare investments. He is currently a director of Liquidia Technologies, Cognoa, K-Gen, Artugen Therapeutics, Cognito Therapeutics, Amylyx Pharmaceuticals, and NuCana BioMed. Previously he was a board member of Advanced Cell Diagnostics (sold to Bio-Techne).
We're inspired by the patients, caregivers, and family members on the front lines of the fight against neurodegenerative diseases. While it's our mission to one day end the suffering caused by these diseases, we'd like to connect you with resources, help, and information along the way.
The CENTAUR trial of AMX0035 was a 24-week, randomized, double-blind, placebo-controlled Phase II clinical trial completed in late 2019, which demonstrated statistically significant treatment benefits for people with ALS.The mission of the Northeast ALS Consortium (NEALS) is to rapidly translate scientific advances into clinical research and new treatments for people with Amyotrophic Lateral Sclerosis (ALS) and motor neuron disease.
The CENTAUR trial of AMX0035 was a 24-week, randomized, double-blind, placebo-controlled Phase II clinical trial completed in late 2019, which demonstrated statistically significant treatment benefits for people with ALS.The mission of the Northeast ALS Consortium (NEALS) is to rapidly translate scientific advances into clinical research and new treatments for people with Amyotrophic Lateral Sclerosis (ALS) and motor neuron disease.
AMX0035 is our first-in-class investigational product - an oral fixed-dose co-formulation of two active compounds, sodium phenylbutyrate (PB) and taurursodiol (TURSO) - optimized to address both the toxic, unfolded proteins in the endoplasmic reticulum and the energy crisis in the mitochondria that occur in neurodegenerative diseases.
Reviews
Be the first to review Amylyx Pharmaceuticals.
Write a Review
